Access comprehensive financial analyses and make smarter investments - get the Manual of Investments on Amazon!

Natera's Stock Soars as Upward Trend Persists

Natera stock is trading -7.28% below its average target price of $230.89 after marking a 3.9% during today's afternoon session. Analysts are giving the Large-Cap Medical Specialities company an average rating of buy and target prices ranging from $186.0 to $250.0 per share.

The stock has an average amount of shares sold short at 3.0%, and a short ratio of 3.4. The company's insiders own 3.11% of its outstanding shares, which indicates a strong alignment between management and shareholder interests. Finally, we also note that a significant number of institutional investors are invested in the stock, with 96.0% of Natera's shares being owned by this investor type.

Institutions Invested in Natera

Date Reported Holder Percentage Shares Value
2025-09-30 Vanguard Group Inc 9% 12,389,033 $2,652,368,029
2025-09-30 Price (T.Rowe) Associates Inc 9% 11,947,415 $2,557,822,033
2025-09-30 JPMORGAN CHASE & CO 8% 11,628,914 $2,489,634,155
2025-09-30 Blackrock Inc. 8% 10,964,351 $2,347,357,865
2025-09-30 Farallon Capital Management LLC 3% 4,253,452 $910,621,523
2025-09-30 State Street Corporation 2% 3,389,599 $725,679,237
2025-09-30 Duquesne Family Office Llc 2% 3,214,532 $688,199,144
2025-09-30 Franklin Resources, Inc. 2% 2,665,013 $570,552,623
2025-09-30 Geode Capital Management, LLC 2% 2,596,955 $555,982,086
2025-09-30 Wellington Management Group, LLP 2% 2,556,062 $547,227,304

Besides an analyst consensus of some upside potential, other market factors point to there being positive market sentiment on Natera.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS